NEW YORK (GenomeWeb) – Natera is aiming to raise $75 million in a follow-on public offering of shares of its common stock, the firm reported after the close of the market on Tuesday. It also expects to grant underwriters a 30-day option to purchase up to an additional $11.25 million worth of common stock.

JP Morgan, Morgan Stanley, and Cowen are acting as joint book-running managers for the offering, which will be made only through a prospectus and related prospectus supplement, copies of which can be obtained from JP Morgan Securities.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.